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 ABSTRACT 
BACKGROUND. This cross-sectional study was performed to determine the 
reference ranges for two bone turnover markers -aminoterminal propeptide of 
type I collagen (P1NP) and C-terminal telopeptide of type I collagen ( -
CrossLaps, -CTX)- in normal postmenopausal Spanish women as determined 
in serum by automated methods. 
METHODS. A community-based population of 1080 healthy postmenopausal 
women was evaluated. Data regarding risk factors for osteoporosis and 
fractures were collected by means of a structured questionnaire. Fasting serum 
levels of P1NP, -CTX, 25-Hydroxivitamin D (25OHD), and intact parathyroid 
hormone (iPTH) were measured on the Elecsys 2010 automated analyzer 
(Roche). BMD at lumbar spine, femoral neck and total hip was determined by 
DXA.  
RESULTS. The mean age of subjects was 63±9. Logarithmic transformation of 
both markers was performed to allow for normal distributions. Mid-95% ranges 
for P1NP and -CTX were 19-100 ng/ml and 0.112-1.018 ng/ml, respectively. 
Mean values of P1NP (47.7±19.9 ng/ml) were similar to those previously 
determined by the manufacturer of the assays, whereas -CTX mean values 
(0.387± 0.197 ng/ml) were lower. Both markers were higher among osteoporotic 
women.  
CONCLUSIONS. Values obtained from this well-characterized population study 
provide reference ranges for serum automated P1NP and -CTX in normal 
Spanish postmenopausal women.  
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1. Introduction 
Osteoporosis is defined as a skeletal disorder characterized by 
compromised bone strength, which predisposes the patient to develop fractures 
[1]. It has been estimated that approximately one-third of all Caucasian women 
over the age of 50 will suffer a fracture of the spine, hip or wrist at some point in 
their life-time [2]. Osteoporosis-related bone fragility results from a combination 
of a decreased bone mass and deterioration in bone microarchitecture along 
with changes in bone tissue quality. Bone loss occurs in postmenopausal 
women as a result of an increase in the rate of bone turnover and an imbalance 
between the activity of the osteoclasts and osteoblasts [3]. Bone turnover 
markers (BTM) reflect whole body rates of bone resorption and bone formation, 
and provide a dynamic assessment of the skeleton which may complement the 
static information given by bone mass evaluation, usually carried out by means 
of bone mineral density (BMD) measurement. The intra-patient variability of 
most BTM, however, has been reported as too high to be recommended in 
general practice, particularly as far as urine measurements are concerned, and 
this fact has limited the spread of their use [4,5]. Nevertheless, sensitivity and 
specificity have improved with the development of assays that evaluate BTM in 
serum, and these new procedures are being incorporated into automated 
equipment which is increasingly being used [6]. 
 Since these automated techniques are now becoming common, the need 
to know the values they provide in the general population, and in particular, the 
values they give in some specific types of people, such as postmenopausal 
women, is increasingly felt. Some publications addressing this issue have 
appeared [6], but values in different countries and regions have to be reported 
and compared. To our knowledge, there is no available information about 
normal values in Spanish postmenopausal women. The Elecsys 2010 (Roche 
Diagnostics, GmbH, Mannheim, Germany) equipment allows the determination 
not only of BTM but also of 25-hydroxyvitaminD3 (25OHD) and intact 
parathyroid hormone (iPTH), a knowledge of which is important for the 
interpretation of BTM results. Therefore, the aim of this study was: i) to evaluate 
these automated methods to measure the serum levels of two BTM, namely 
aminoterminal propeptide of type I collagen (P1NP) and C-terminal telopeptide 
of type I collagen ( -CrossLaps, -CTX), in Spanish postmenopausal women, 
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and ii) to analyze their relationship with 25OHD and PTH serum concentrations 
provided by the same equipment. BMD measurements were also performed, 
and the relationship of their results with BTM, 25OHD and PTH analyzed.  
 
2. Material and methods 
 
2.1. Study design and participants  
 
The study population was set up with postmenopausal women included 
in the Camargo Cohort Study, a community-based study designed to evaluate 
the prevalence of metabolic bone diseases and the prevalence of risk factors for 
osteoporosis and fragility fractures in postmenopausal women and men older 
than 50 attended at a primary care centre in Northern Spain. A total of 1350 
consecutive postmenopausal women attending the clinic for whatever reason 
were initially included, after giving informed consent. All participants were white, 
as are more than 95% of people in our region (Cantabria). Some 100 
premenopausal women aged 26-50 (mean± SD: 42±6 years), randomly 
recruited among healthy nonpregnant women from Camargo, were also studied 
at the same time for the sake of comparison with postmenopausal women. The 
local Ethic Committee approved the study protocol.  
At the baseline visit, subjects were interviewed by investigators and all 
participants provided data regarding the risk factors of osteoporosis and 
fractures using a structured questionnaire which included age, race, weight, 
height, body mass index (BMI, defined as weight in kg. divided by squared 
height in meters), personal antecedents of fractures in adulthood (> 40 years), 
history of osteoporotic fractures among first-degree relatives, tobacco use, 
consumption of dairy products, alcohol consumption, physical exercise, the 
existence of sensory problems, the number of falls in the previous year, the 
presence of chronic diseases (hypertension, dyslipemia, diabetes mellitus, 
urolithiasis, hyperthyroidism, hyperparathyroidism, etc), and present or past 
consumption of medications.  
Postmenopausal women in which the baseline assessment revealed the 
presence of diseases or treatments known to affect bone metabolism, such as 
osteoporosis, primary hyperparathyroidism, hyperthyroidism, serum creatinine > 
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151 mol/L, or treatment with bisphosphonates, oestrogen, raloxifene, strontium 
ranelate, teriparatide, L-thyroxin or glucocorticoids, were excluded from the 
study. Therefore, those women previously diagnosed and treated for 
osteoporosis were left out. However, those women who were found to be 
osteoporotic as a result of our BMD study, were included and evaluated. None 
of premenopausal women had diseases or treatments that could interfere with 
bone metabolism 
2.2. Biochemical tests 
 
For each woman, fasting blood samples were collected between 09:00 
and 10:30 h. Serum was divided into 0.5-ml aliquots and stored at -40ºC. Serum 
total calcium (TCa), phosphate, creatinine, albumin, and total alkaline 
phosphatase were measured by standard automated methods in a Technicon 
Dax autoanalyser (Technicon Instruments, CO. USA). TCa measurements were 
corrected for albumin concentration (cCa) following a previously published 
formula [7]. Serum concentrations of P1NP, -CTX, 25OHD, and iPTH were 
determined by a fully automated Roche electrochemilluminiscence system 
(Elecsys 2010, Roche Diagnostics, GmbH, Mannheim, Germany). The P1NP 
limit of detection was 5 ng/ml (reference range between 20-76 ng/ml), and its 
intraassay and interassay coefficients of variation (CV) were 3.1% and 3.5%, 
respectively [8].  Intraassay and interassay CV for β-CTX were 4.2% and 4.7%, 
also respectively, and the detection limit was 0.01 ng/ml [6]. The detection limit 
of serum 25 OHD was 4 ng/ml, its intraassay CV 5%, and its interassay CV 
8.5%. Regarding intact PTH, the detection limit was 6 pg/ml, with a normal 
range of 15-65 pg/ml. Intraassay and interassay CV were 5.4% and 5.9%, 
respectively [9]. 
 
2.3. DXA measurements  
 
BMD was measured by DXA (Hologic QDR 4500, Bedford, MA, USA) at 
the lumbar spine, femoral neck, and total hip in all the 1080 women who finally 
entered the study (see below). In vivo precision was 0.4-0.5% at the different 
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measurement sites. Results were expressed as grams per square centimetre, 
T-score (defined as the number of standard deviations [SDs] below the mean 
value of young women), and Z-score (defined as the number of SDs below the 
mean of women of the same age). T and Z-scores were calculated using the 
NHANES III reference database for femur measurements [10]. Quality control 
was performed according to the usual standards [11]. 
2.4. Statistical analyses 
 
Results were expressed as mean ± SD for quantitative variables and 
percentages for qualitative variables. As expected in postmenopausal women, 
serum β-CTX and P1NP were not normally distributed with a frequency 
distribution skewed to the left (Figure 1A and 1B). Thus, these variables 
underwent logarithmic transformation before statistical analyses. Chi-squared or 
Fisher’s exact test were performed in order to identify differences in categorical 
variables between subgroups. Mann-Whitney U-Test was used to compare 
BTM between the groups of women distributed by serum levels of iPTH, vitamin 
D, or osteoporosis status. One-way ANOVA was undertaken to assess 
correlation between BTM and age strata. Bonferroni’s test for multiple 
comparisons was performed when significant differences were found. 
Significance levels less than 5% were considered significant. All analyses were 






A total of 1350 postmenopausal women, aged 44-93, with no menses for 
at least 12 months were recruited. Some 270 were excluded because their 
baseline study revealed the presence of diseases or treatments known to affect 
bone metabolism, or even treatments addressed to bone metabolic diseases, 
including osteoporosis. The remaining 1080 women entered into the study, and 
their characteristics are listed in table 1. 
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3.2. Serum P1NP and -CTX levels 
 
Mean serum P1NP and -CTX in postmenopausal women were 47.7 
ng/ml (± 19.9) and 0.387 ng/ml (± 0.197) respectively (Table 2). Neither of them 
was distributed normally, but skewed toward the lowest values (Fig.1A, and 1B). 
After log- transformation, data in the two cases took on a normal, Gaussian 
distribution, and the geometric mean ± 2SD was used to determine the 95% 
range. The limits of this range were 19-100 ng/ml for P1NP, and 0.112-1.018 
ng/ml for -CTX (table 3). In premenopausal women, mean P1NP (41.1±18.5 
ng/ml) and -CTX (0.271±0.139 ng/ml) were significantly lower (p<0.001). In 
relation to these, postmenopausal levels were, respectively, 18% and 43% 
higher.  
3.3. Changes in serum P1NP and -CTX with age 
 
Considering all postmenopausal women as a whole, no significant 
correlation between age and either P1NP or CTX concentrations was found. 
However, a U-shaped relationship was visually appreciated (Fig.1C, and 1D), 
so that both BTM serum levels decrease up till the age of 70-79 y. (r correlation 
coefficient between age and P1NP, -0.154 [p<0.0001]; between age and CTX, -
0.114 [p <0.0001]), with a rise afterwards which reached a significant level for 
CTX (p=0.01, “t” test), and showed a trend for P1NP (p=0.06). Changes were 
somewhat more pronounced for CTX (about 30%) than for P1NP (20%).  
3.4. Comparison of BTM between subgroups 
 
Different subgroups were set up according to several criteria (presence 
or absence of densitometric osteoporosis; serum PTH above or below 65 pg/ml 
– the upper limit of normal -; and serum 25OHD above or below 30 ng/ml), and 
their corresponding P1NP and CTX values compared (Table 4). As expected, 
the two markers were higher in postmenopausal women with osteoporosis than 
in postmenopausal women without (p<0.001), the difference being 7.1% for 
P1NP and 14.6% for CTX.  Regarding the differences between osteoporotic 
and premenopausal women, the respective differences amounted to 23% and  
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61%. Since the corresponding SD are in the range of 45% and 60% of 
premenopausal values, there is a marked overlap between both populations. 
Women with PTH levels above the upper limit of normal also had higher 
levels of CTX (p<0.05), but not of P1NP. Regarding 25OHD, BTM tended to 
be higher in women with values above 30 ng/ml, although the difference was 
significant only for P1NP (p<0.05). This difference disappears however after 
adjusting for weight, a finding that was expected, since both 25OHD and BTM 
levels are inversely related to weight.  
Finally, we did not find any relationship between smoking habits, alcohol 
consumption, physical activity, and the other characteristics of the population 
studied  (Table 1) and bone mineral markers (data not shown). 
 
3.5. BMD in postmenopausal women according to BTM values 
 
The relationship between BTM and BMD was also analyzed categorizing 
women in quartiles according to bone marker levels, and comparing the BMD 
values. Women with P1NP and -CTX levels in the lowest quartile had a lumbar 
spine BMD 4% and 7% greater than in the highest (P1NP: 0.934±0.129 g/cm2 
vs. 0.894±0.123 g/cm2; p<0.05; -CTX: 0.952±0.132 g/cm2 vs. 0.883±0.123 
g/cm2; p<0.05). A similar pattern was seen at the femoral neck (P1NP: 
0.748±0.118 g/cm2 vs. 0.705±0.095 g/cm2; p<0.01; CTX: 0.761±0.121 g/cm2 
vs. 0.670±0.098 g/cm2; p<0.001) and the total hip (P1NP: 0.888±0.120 g/cm2 
vs.0.836±0.106 g/cm2; p<0.01; -CTX: 0.913±0.122 g/cm2 vs. 0.831±0.110 
g/cm2; p<0.001). BMD differences between the highest and lowest quartiles 
were greater when based on -CTX than on P1NP. 
   
 
4. Discussion 
New automated techniques to determine bone markers are becoming 
increasingly common, and therefore their normal reference values must be 
established. The manufacturers have developed their own reference values [6], 
but normal levels for different countries, or even regions, must be defined and 
compared. We have studied the serum levels of P1NP and -CTX determined 
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by the Elecsys 2010 equipment (Roche Diagnostics) in 1080 Spanish 
postmenopausal women in which mineral metabolic disorders, bone  metabolic 
diseases (other than previously unknown osteoporosis) and treatments known 
to affect bone metabolism had been ruled out. The sample met the criteria for 
postmenopausal BTM reference individuals recommended by the Clinical and 
Laboratory Standards Institute (NCCLS) [12]: it was large enough, the 
participants were well-characterized, and all women provided data regarding 
their risk factors for osteoporosis and fractures. In addition, all samples were 
obtained at the same time of the day and in a fasting state, so that factors 
leading to biological variability could be controlled. Mean serum P1NP and -
CTX were 47.7 ng/ml (± 19.9) and 0.387 ng/ml (± 0.197). The ± 2SD range 
limits (after log-transformation) were 19-100 ng/ml for P1NP and 0.112-1.018 
ng/ml for -CTX.  
The mean and reference values that we have found for P1NP in our 
postmenopausal women are similar to those described by the manufacturers in 
the OFELY cohort [6]. Moreover, mean values of P1NP in our osteoporotic 
women (50.5±18.6 ng/ml) were also similar to values reported recently by 
Garnero et al [8] in 238 postmenopausal osteoporotic women from the US using 
the same methodology. Therefore, P1NP values assessed by the Elecsys 
automated method appear to be similar in Caucasian women in different 
countries.  
In contrast to P1NP, serum -CTX determined by the automated assay 
appears to show some differences among various publications. The 
manufacturer reference values are those reported by Garnero et al in 429 
French postmenopausal women (age range, from 45 to 80 or more years) from 
the OFELY cohort [6], and amount to 0.556±0.226 ng/ml. These values are in 
clear contrast to those of our own study, which were 0.387± 0.197 ng/ml. 
Similarly, they differ from the values reported by Boudou et al [13] in 30 normal 
French postmenopausal women, for which a range of 0.13-0.60 ng/ml was 
found (mean level not given). Trento et al [14], in 200 Italian recent 
postmenopausal women (54.6±6.1 years) attending a menopause centre found 
values of 0.45±0.10 and 0.47±0.12 ng/ml in women with normal or osteopenic 
BMD values respectively. In our sample, women of this age showed a mean 
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value of 0.405±0.200 ng/L. In a study performed by Lenora et al [15] in 75-year 
old women from Malmo, Sweden (the OPRA study), serum -CTX levels were 
0.312±0.186 ng/L. Again, in our sample, women of this age showed a similar 
value of 0.353±0.178 ng/ml. On the other hand, Chen et al [16] reported a value 
of 0.31 ng/ml (range 0.20-0.47) in frail elderly (older than 80) women from 
Sydney, Australia. At this age, in our sample -CTX levels were 0.435±0.220 
ng/ml.  
Therefore, there seem to be wide differences regarding -CTX results, 
which range from 0.556±0.226 ng/ml in normal postmenopausal women in the 
French OFELY cohort to 0.31 ng/ml (range 0.20-0.47) in frail elderly women 
from Australia (almost a 100% difference). These two extreme values are, 
respectively, about 47% higher and 28% lower than those of our own cohort. On 
the other hand, no such big differences are found between our results and 
those of the other publications. Thus, our values are just about 10% higher and 
10% lower than those of Lenora et al [15] and Trento et al [14], respectively, 
and very close to those of Boudou et al. [13]. 
Some of these differences could be accounted for by the particular 
characteristics of women included in each study, such as age, weight, smoking 
habits, physical activity, etc. A higher proportion of women with osteoporosis, 
for instance, could result in higher -CTX values. In this regard, OFELY cohort 
data [6] are of particular interest, since the serum -CTX levels of this 
population, while considered the reference values by the ELECSYS 2010 
manufacturer, are clearly above those of the rest of the studies.  
All these uncertainties emphasize the importance –or even the necessity- 
of establishing reference values for different populations, and the interest of 
carrying out comparisons [17].  
In conclusion, in our study we report the mean and reference ranges for 
BMT (P1NP and -CTX) from a well characterized population of Spanish 
postmenopausal women, using a new automated technique. For serum P1NP, 
these values were similar to those previously reported by the equipment 
manufacturers, while for -CTX they were lower. Although population 
differences always remain an explanation, we rather believe that manufacturer 
reference values for -CTX may be overestimated. We trust that our reference 
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ranges can serve as useful standards for bone turnover in postmenopausal 
women in our country. 
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List of abbrevations 
 
P1NP: Aminoterminal propeptide of type I collagen   
β-CTX:  C-terminal telopeptide of type I collagen  
25OHD: 25-Hydroxivitamin D 
iPTH: intact parathyroid hormone 
BMD: Bone mineral density  
LS: Lumbar spine 
FN: Femoral neck 
TH: Total hip 
DXA: Dual X-ray absorptiometry 
BMT: Bone turnover markers  
SD: Standard deviation 
BMI: Body mass index  
TCa: serum total calcium  
cCa : Albumin-corrected serum total calcium 
CV: Coefficients of variation  
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Figure 1. Frequency  distribution of serum P1NP (A) and -CTX  (B) in 
postmenopausal women. Age-related changes in serum P1NP (C) and -CTX 
(D) in postmenopausal women  
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 Mean± SD 
(n=1080) 
Range 
Age (years) 63 ± 9 44-93 
Weight  (Kg) 70 ± 12 43-120 
Height (cm) 156 ± 6 138-175 
BMI (Kg/m2) 28.8 ± 4.8 16-49 
Waist’s perimeter (cm) 96 ± 13 60-148 
Arm spam (cm) 158 ± 8 111-185 
Age of menarche (ys) 13 ± 2 9-19 
Age of menopause (ys) 49 ± 5 27-60 
History of falls (last year) (%) 27 - 
Any fracture > 40 ys (%) 16 - 
Physical activity 
      Sedentarism (%) 
      Moderate (%) 









Current smoking (%) 12 - 
Current alcohol consumption (%) 12 - 
Dairy calcium consumption (mg/day) 683 ± 331 0-2300 
Calcium supplements (%) 8 - 
Vitamin D supplements (%) 7 - 
Dyslipemia (%) 29 - 
Diabetes mellitus (%) 11 - 
Urolithiasis (%) 12 - 
Table(s)
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Table 2. Biochemical parameters and bone mineral density (BMD) in 




cCa : Albumin-corrected serum total calcium; P1NP: Aminoterminal propeptide 
of type I collagen ; -CTX:  C-terminal telopeptide of type I collagen; 25OHD: 
25-hydroxyvitamin D; iPTH intact parathyroid hormone. BMD, LS: Bone mineral 
density at the lumbar spine; BMD, FN: Bone mineral density at the femoral 
neck, BMD, TH: Bone mineral density at the total hip. 
 Mean ± SD 
(n=1080) 
Range 
Glucose (mmol/L) 5.27 ± 1.27  3.38-16.92 
Creatinine ( mol/L)        83.98 ± 8.84 44.22-150.28 
Calcium (mmol/L)          2.42 ± 0.1    2.07-2.57 
Phosphate (mmol/L)          1.13 ± 0.16 0.35-1.64 
Albumin (g/L)             45 ± 3 30-56 
cCa (mmol/L)          2.30 ± 0.07 2.11-2.55 
Alkaline phosphatase (U/L)              72± 19  29-171 
25OHD (ng/ml)             23 ± 9 4-90 
iPTH (pg/ml) 52 ± 16 9-98 
P1NP (ng/ml) 47.7 ± 19.9  11.9-187.7 
-CTX (ng/ml)  0.387 ± 0.197  0.03-1.44 
BMD, LS (g/cm2)   0.924 ± 0.139  0.532-1.416 
BMD, LS (T-score) -1.40 ± 1.27 -4.97-3.06 
BMD, LS (Z-score) 0.25 ± 1.35 -3.17-5.13 
BMD, FN (g/cm2)  0.729 ± 0.117  0.399-1.138 
BMD, FN (T-score) -1.09 ± 1.05 -4.13-2.60 
BMD, FN (Z-score) -0.09 ± 1.12 -2.57-4.87 
BMD, TH (g/cm2)  0.857 ± 0.122  0.493-1.264 
BMD, TH (T-score) -0.69 ± 1.00 -3.70-2.64 
BMD, TH (Z-score)  0.44 ± 1.01 -2.76-3.79 
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Table 3. Reference ranges and means for serum bone turnover markers 
(BMTs) in postmenopausal women 
 
 Serum P1NP (ng/ml) Serum -CTX (ng/ml) 
Study (N) 1080 1080 
Ref. range 19-100 0.112-1.018 
Mean 47.7 0.387 
(SD) (19.9) (0.197) 
Median 44.5 0.356 
Manufacturer (N) 290 429 
Ref. range 20-76 NA 
Mean 45.1 0.556 
(SD) NA 0.226 
Median 42.9 NA 
 
P1NP: Aminoterminal propeptide of type I collagen ; -CTX:  C-terminal 
telopeptide of type I collagen. NA: Not available. 
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Table 4. Subgroup analysis of mean serum (±SD) P1NP and -CTX among 
healthy postmenopausal women according to age, serum levels of 25OHD and 
PTH, and the presence or absence of osteoporosis 




Age (years)  1080   
 <50 44 55.2±19.5 0.462±0.205 
 50-59 444 49.8±19.2 0.405±0.200 
 60-69 322 46.2±19.2 0.366±0.190 
 70-79 212 43.5±16.5 0.353±0.178 
 >80 58 50.0±24.9 0.435±0.220 
25OHD  1080   
 <=30 ng/ml 874 47.2 ± 20.1 0.384 ± 0.197 
 >30 ng/ml 206 50.2 ± 19.1* 0.400 ± 0.192 
iPTH  1080   
 <=65 pg/ml 863 47.7 ± 20.1 0.378± 0.193 
 >65 pg/ml 217 47.9 ± 19.6   0.426 ± 0.206** 
Osteoporosis  1073   
 Yes 224    50.5 ± 18.6** 0.438 ± 0.187*** 
 No 849 46.9 ± 20.3 0.374 ± 0.197 
 
*p<0.05; **p<0.01; ***p<0.0001 
P1NP: Aminoterminal propeptide of type I collagen ; -CTX:  C-terminal 
telopeptide of type I collagen; 25OHD: 25-hydroxyvitamin D; iPTH intact 
parathyroid hormone  
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